Life Sciences Summit 2013
We’re delighted to welcome this panel of experts to discuss how early stage companies can attract funding...
Norwood, MA and New York, NY (PRWEB) October 17, 2013
Kimberly Ha, Global Editor for BioPharm Insight, will moderate a panel discussion on early-stage pharmaceutical company investment strategies at the Life Sciences Summit, sponsored by Demy-Colton Life Science Advisors, New York City, November 21 from 9-10 am EST.
The Life Sciences Summit is dedicated to bringing emerging companies and innovators together with capital and industry in a setting that facilitates collaboration and networking. The Summit’s program convenes business leaders, KOLs, emerging companies and innovators to accelerate the development of new therapies to address unmet medical needs. To learn more and register for the Life Science Summit, visit http://bit.ly/1fZXPXR.
Kimberly Ha will moderate the following Plenary Session:
“Investors Speak: What Does an Early Stage Company Need to Do to Earn Support?”
Venture investment in biotech has increased over the course of 2013, thanks in part to the best market for IPOs in years. But early stage companies still face an uphill battle to secure funding. What are investors looking for in preclinical/Phase I companies? This panel of expert early-stage investors will share their investment criteria and offer insight into how young drug companies can gain investor support.
Joining Kimberly will be panelists:
- Laurence Blumberg MD, Senior Vice President, Project Management, Kadmon Corporation, LLC
- Alex Zisson, Partner, Thomas, McNerney & Partners LLC
- Les Funtleyder, Healthcare Strategist, Polliwog
- Anthony Sun, Partner, Aisling Capital
Last month, Kimberly Ha moderated a panel to discuss challenges and opportunities in funding drug development at Demy-Colton’s US-Japan Health Sciences Dialogue.
Sara Jane Demy, Founder of the Life Sciences Summit, said, “We’re delighted to welcome this panel of experts to discuss how early stage companies can attract funding, and to have a journalist of Kimberly Ha’s caliber leverage her insights and market knowledge as our moderator again.”
Kimberly Ha is an award-winning biopharmaceutical industry journalist and editor. She launched BioPharm Insight's editorial team in 2007. Kimberly began her career as a financial journalist in Hong Kong specializing in healthcare M&A, and previously was the lead sector specialist at Mergermarket, a division of the Financial Times Group. She is a sought-after panelist and moderator at major healthcare investor conferences and events. A member of the Galien Foundation Advisory Board, Kimberly has received fellowships from organizations including the National Press Foundation, the UN Foundation for Global Vaccines, and the Association of Health Care Journalists.
About BioPharm Insight
BioPharm Insight is the definitive guide to the global healthcare community. BioPharm Insight provides subscribers with an information edge by combining the most comprehensive real-time database of market analytics, key industry contacts, and proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit http://www.biopharminsight.com.
About Infinata, Inc.
Infinata provides personalized technology solutions to turn information into insight. Services include a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit http://www.infinata.com.
Business Inquiries: Holly Burke, hburke[at]infinata[dot]com, 781-619-0131
Media Inquiries: Brenda Nashawaty, Brenda(at)nashawaty(dot)com, 617-688-3253